In December, Vanda Pharmaceuticals gained FDA approval for its motion sickness drug Nereus. But a much larger patient population may be in store for the oral therapy as the Washington, D.C.-based ...

Samson has launched to a fair bit of flak, which is, in many ways, unfair, as it is a $25 game. Its biggest problem is that people really want it to be a great game, so they have kicked it as it was ...

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead. Lilly is looking to repeat its success in ...

(WHTM) — The snack industry feels the side effects as more people use GLP-1 weight-loss drugs. The Hershey Company listed GLP-1 as a headwind affecting chocolate sales, alongside economic stress and ...

After completing a degree in Film, Television, and Cultural Studies at Manchester Metropolitan University, I decided to pursue my love of writing and video games by entering the world of video game ...

Bohemia Interactive has delivered the newest update for DayZ. The zombie survival game has received new assets, technical support, and wipes for characters and servers. Here’s the full rundown for ...

Share on Pinterest Could a new oral option help to meet the growing demand for GLP-1 medications? Image Credit: Medical News Today/Photo by Eli Lilly The Food and Drug Administration (FDA) has ...

The GLP-1 weight loss drugs revolutionizing the treatment of obesity, diabetes and a slew of other diseases come with a major caveat: They don’t work for everyone. Some people experience profound ...

Matthew Herper covers medical innovation — both its promise and its perils. Specific changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs used to ...

Of all the millions of people who have tried weight-loss drugs such as Wegovy and Zepbound, nearly one in four people don’t respond to treatment. They lose little weight, or none at all, and see few ...

23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 ...

Ruth J. F. Loos is in the Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark. Read the paper: ...